PUBLIC PORTAL

HSA Approves First-In-Class Sacituzumab Govitecan (Trodelvy) for Metastatic Triple Negative Breast Cancer (mTNBC)

Disease burden and treatment landscape
Breast cancer is the leading cause of death among Singaporean women and accounts for over 30% of all cancers diagnosed in women. It is a . . .

Login or Sign Up as a healthcare professional to read the full article.

PEOPLE WHO READ THIS ALSO READS